Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$68.12 USD
+1.62 (2.44%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $68.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.12 USD
+1.62 (2.44%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $68.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Zacks News
Here's Why You Should Invest in Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.
NextGen Healthcare Boosts Patient Care With CHC Strategies
by Zacks Equity Research
NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.
Here's Why You Should Retain NextGen Healthcare for Now
by Zacks Equity Research
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
Here's Why You Should Retain Wright Medical Stock For Now
by Zacks Equity Research
Wright Medical (WMGI) is gaining traction from strong international presence and robust product portfolio. However, adverse forex continues to raise concerns.
Edwards Lifesciences (EW) Plans Strong Long-Term TAVR Growth
by Zacks Equity Research
Within TAVR, Edwards (EW) expects global TAVR opportunity to exceed $7 billion by 2024.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.
NuVasive (NUVA) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
Patterson Companies (PDCO) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) Q2 results benefit from higher revenues, gross margin expansion and solid show by Dental segment.
What's in the Cards for Cantel Medical (CMD) in Q1 Earnings?
by Zacks Equity Research
Better-than-expected performance at both Medical and Dental segments is likely to have driven Cantel Medical (CMD) in Q1 earnings.
Here's Why You Should Hold On to HMS Holdings (HMSY) Stock
by Zacks Equity Research
HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services. However, high debt continues to raise concerns.
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Better-than-expected performance at CVI and CSI, and higher revenues are likely to have aided Cooper Companies (COO) in Q4 earnings.
Edwards Lifesciences (EW) Up 6.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in the Cards for Veeva Systems (VEEV) in Q3 Earnings?
by Zacks Equity Research
Robust product portfolio and higher revenues are likely to have benefited Veeva Systems (VEEV) in third-quarter fiscal 2020 earnings.
Edwards Lifesciences, Fossil, United Airlines and Boeing highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Edwards Lifesciences, Fossil, United Airlines and Boeing highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Edwards Lifesciences (EW)
by Tracey Ryniec
This medical innovator is a superstar stock.
Top Analyst Reports for Apple, Comcast & NVIDIA
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Comcast Corporation (CMCSA) and NVIDIA Corporation (NVDA).
Edwards Lifesciences (EW) Recalls PASCAL's Guide Sheath
by Zacks Equity Research
Edwards Lifesciences (EW) issues a product recall for its guide sheath based on report from its urgent field safety notice.
Top & Flop ETFs of Last Week
by Sanghamitra Saha
Cocoa ETF was a hot trade last week while cannabis ETF lost the most.
Haemonetics (HAE) Grows on New Products, Robust Plasma Sales
by Zacks Equity Research
Haemonetics (HAE) witnesses a steady uptick in Plasma franchise, fueled by favorable price, volume and mix.
Will Edwards Lifesciences (EW) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Edwards Lifesciences (EW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Is Edwards Lifesciences (EW) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Edwards Lifesciences (EW) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Penumbra's (PEN) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Penumbra (PEN) witnessed strong growth across all geographies and product lines in Q3.
Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.